secwatch.observer — SEC 8-K summary
======================================

Issuer:     Assertio Holdings, Inc. (ASRT)
CIK:        0001808665
Form:       8-K/A
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001104659-26-041569
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assertio to be acquired by Garda Therapeutics in $18.00/share cash tender offer plus CVRs
--------------------------------------------------------------------------------

- Acquisition by Garda Therapeutics at $18.00/share cash plus one CVR per share; tender offer to commence within 10 business days.
- Asset sale to Cosette Pharmaceuticals for $35M cash upfront plus up to $32M in milestone payments and SPRIX-related CVR payments.
- Equity commitment of $17M from Joseph Limber and Brett Lund; debt commitment of $87M from Colbeck Capital Management.
- Termination fee: $4.8M standard, reduced to $1.75M for a Qualified Bidder prior to Window Shop End Time.
- CEO Mark Reisenauer's non-compete extended to 18 months post-termination in connection with the merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808665/000110465926041569/0001104659-26-041569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808665/000110465926041569/tm2611405d4_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-041569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer